News
-
-
-
PRESS RELEASE
Nebius launches Physical AI Living Lab for UK and European robotics startups built with NVIDIA technologies
Nebius launches Physical AI Living Lab for UK and European robotics startups built with NVIDIA technologies. Program to accelerate real-world deployment and remove infrastructure barriers -
-
-
PRESS RELEASE
THX Pharma, Biocodex and the Beyond Batten Disease Foundation Stand Together with the CLN3 Batten Community on International Batten Disease Awareness Day
Join THX Pharma, Biocodex, and BBDF as Platinum Sponsors at the 2026 BDSRA Family Conference to provide an update on the Batten-1 program and Phase 3 study for CLN3 Batten disease -
-
PRESS RELEASE
Fireaway Achieves Type Approval and EU/UK Marine Equipment Certification for Stat-X® Condensed Aerosol Fire-Extinguishing Systems Following MSC.1/Circ.1270 Evaluation
Fireaway Inc. receives type approval and EU/UK marine equipment certification for Stat-X® condensed aerosol fire-extinguishing systems following MSC.1/Circ.1270 evaluation, enhancing safety in SOLAS-regulated marine environments -
PRESS RELEASE
EQS-Adhoc: K+S Aktiengesellschaft: K+S launches an offering of approximately €300 million convertible bonds due 2031
K+S Aktiengesellschaft launches offering of €300 million convertible bonds due 2031. Bonds offered via private placement to institutional investors for financing purposes -
PRESS RELEASE
EQS-Adhoc: Pentixapharm Holding AG: FDA grants “Study May Proceed” for Phase 3 Study; Intended Capital Increase with Subscription Rights of up to 10 Million Shares; BaFin Financial Reporting Enforcement Review
Pentixapharm Holding AG receives FDA clearance for Phase 3 study, plans capital increase of up to 10 million shares with subscription rights, and faces BaFin financial review
![Logo of [UNKNOWN]](https://logos.symex.be/img/.jpg)
